Eczema verergt en kalmeert, gedreven door een lekke huidbarrière en een overactief immuunsysteem. De zorg die het onder controle houdt is eenvoudig: veel hydrateren en uitbraken kalmeren met een topische steroïde. Angst voor dat crèmepreparaat richt meer schade aan dan de crème zelf, omdat mensen die ervan bang zijn te weinig gebruiken en hun eczeem actief laten. Calcineurinemodulatorcrèmes zijn geschikt voor het gezicht en andere delicate huid, en een tweemaal per week aangebrachte anti-inflammatoire crème voorkomt de volgende uitbraak. Voor eczeem over een groot deel van het lichaam dat niet kalmeert, zijn dupilumab en JAK-remmer-tabletten effectief.
Twee populaire ideeën faalden in hun proeven. Dieetmet voedseluitsluiting helpt weinig bij de meeste vormen van eczeem en kan een nieuw voedselallergie uitlokken. Dagelijks babyvochtinbrengende crème voorkwam geen eczeem bij zuigelingen met een hoog risico. Er is één noodsituatie: eczeem herpeticum.
Practice Ranking
Every practice we track for Eczema (Atopic Dermatitis): calming the skin, ranked by how well the evidence supports it for this condition. Strength describes the evidence, not our endorsement.
2 practices · 0 to start with
| # | Practice | Evidence | Type | Cost | Effort | Results In | Add to plan |
|---|---|---|---|---|---|---|---|
| 1 | Vitamin D Vitamin D helps eczema mainly in people who are deficient, a cheap add-on rather than a standalone fix. | Emerging | Supplement | $ | Easy | Weeks to Months | |
| 2 | Probiotics: Which Strains Work, For What, and Who Should Take Care For eczema you already have, probiotics made little or no difference, so they are not worth relying on. | Moderate | Supplement | $ to $$ | Easy | Days to Weeks | |
Default order puts the best-supported practices first, with self-directed care ahead of clinical options. Click any row to open the practice.
What It Is
Eczema, or atopic dermatitis, is a condition of the skin barrier and immune system. It affects around one in five children and about one in twenty adults, and it runs in flares and calmer spells. Where it comes from points to the treatment that works.
The outer layer of skin is meant to hold water in and keep irritants, allergens and microbes out. In eczema that barrier is leaky. The strongest known risk is an inherited weakness in a skin protein called filaggrin. It lets moisture escape and lets irritants and allergens through. The immune system overreacts to what gets in, and the inflammation weakens the barrier further. This is why the skin is dry, why it flares, and why treating the skin is the foundation of care.
The itch is the worst of it, and it drives a cycle. Scratching relieves it for a moment. It damages the barrier a little more, letting in more of what inflames the skin, so it itches more. Flares settle into familiar places: the creases of the elbows and knees, the wrists, the ankles and the neck, and in babies the cheeks and scalp. The trigger for a flare differs from person to person:
- heat and sweat
- harsh soaps
- low humidity
- wool worn straight against the skin
- stress
Eczema often comes first in a sequence called the atopic march. That sequence can go on to include food allergy, asthma and hay fever, because the same barrier-and-immune tendency underlies all three. Having eczema does not mean the rest will follow, though it explains why they often travel together.
What Helps
The care that works for eczema is mostly done at home, day after day. Two measures do the most and are the most underrated: moisturizing a lot, and using the anti-inflammatory cream properly when the skin flares.
Moisturizing does the most of anything you do at home. Applied generously and often, all over and every day, plain emollients roughly halved flares in the trials. They pushed the next flare from about a month away to about six months away, and they cut how much steroid cream people needed. The amount matters more than the brand. Keep it up even when the skin looks clear, because that is what holds the next flare off.
Topical steroid creams are the main treatment that settles a flare, and used correctly they are safe. In the trials about two in three people improved on the steroid, against about one in three on the moisturizer base. Side effects were no more common than in the moisturizer group. Use them in short courses on active eczema, at a potency matched to the site: mild on the face, stronger on thick skin. The thinning people worry about comes from prolonged strong steroids on delicate areas; short courses used as directed do not cause it.
The belief that these creams are dangerous keeps eczema undertreated. In the studies that measured it, people who feared the cream skipped treatment far more often, with nonadherence around 49% against 14%.
People who are scared of the cream use too little of it, so their eczema stays active and the fear ends up doing more harm than the treatment.
Tacrolimus and pimecrolimus, the topical calcineurin inhibitors, control eczema without steroids. In the large network of trials they improved five to six of seven eczema outcomes without increasing harm. They do not thin the skin, so they are the first choice for the face, the eyelids and the skin folds, where prolonged steroids are riskiest. A short-lived stinging when first applied usually settles within a week.
Once the skin is calm, twice-weekly maintenance keeps it calm. Dabbing an anti-inflammatory cream on the usual trouble spots twice a week pushed the median time to the next flare. It went from 15 days to 142 days in the trial that tested it. Keep treating the skin that keeps flaring even after it looks normal, and the next flare is prevented instead of chased.
Two bathing measures help at the more troublesome end. For eczema that keeps getting infected, dilute bleach baths calmed clinician-rated severity by around 22%. The recipe is about half a cup of standard bleach in a full tub, two or three times a week, followed by rinsing and moisturizing. Plain lukewarm water baths did nearly as well, so much of the benefit is the bathing-and-moisturizing routine itself. The plain version is fine if the bleach is off-putting.
For a severe flare, wet wraps, damp bandages laid over emollient and steroid, can settle the skin quickly for a few days. The formal evidence that they beat ordinary steroid treatment is thin. They can slightly raise the chance of a mild skin infection, so they are kept to a few days and are not routine care.
For eczema that covers much of the body and does not respond to creams, there are effective specialist options. Dupilumab is an injected biologic that blocks the type-2 inflammation central to eczema. It cleared or nearly cleared the skin in about a third of people, against under one in ten on placebo, and it calmed the itch alongside.
The oral JAK inhibitors, such as abrocitinib and upadacitinib, work fast and strongly. In a head-to-head trial abrocitinib eased itch faster than dupilumab, 48% against 26% reaching a meaningful itch improvement by two weeks. They need blood-test monitoring and carry class safety warnings, so they belong in a dermatology clinic.
Phototherapy sits between the creams and these systemic drugs. A course of narrowband UVB light at a clinic eased eczema and itch in the trials, on low-certainty evidence. It means regular visits instead of a tablet or an injection.
Two lower-key options are worth a mention, both well behind the mainstays on the evidence. A vitamin D supplement is a cheap, low-risk add-on that modestly improved severity in the pooled trials. It makes the most sense if your levels are low or during the darker months. Chinese herbal medicine showed a modest edge on recovery rates in the trials. The full research, graded at its own strength, is here.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Skin And Hair
Lokale steroïden brachten eczeemopflakkeringen tot bedaren bij 65% van de mensen, tegenover 32% met de basiscrème
Steroïdcrèmes zijn de belangrijkste behandeling die een eczeemopflakkering tot bedaren brengt. In de onderzoeken verbeterde ongeveer twee op de drie mensen met de steroïde, tegenover ongeveer één op de drie met de vochtinbrengende basis, en bijwerkingen kwamen niet vaker voor dan in de groep met vochtinbrengende crème.
Deze meta-analyse voegde de gegevens samen van 12 RCT's (2224 deelnemers) van lokaal corticosteroïd tegenover basiscrème of vochtinbrengende crème bij eczeem op kinderleeftijd. De respons was 0.65 (95%-BI 0.54 tot 0.74) met steroïde tegenover 0.32 (0.20 tot 0.48) met de basiscrème, met vergelijkbare bijwerkingen (0.17 vs. 0.12). Milde, omkeerbare bijniersuppressie werd geregistreerd bij 4 van de 157 geteste kinderen (3%). Tien van de twaalf onderzoeken werden gesponsord door de industrie en de heterogeniteit was hoog, dus de effectgrootte is bij benadering; de richting van het voordeel staat niet ter discussie en is consistent met het bredere richtlijnbewijs.
Gebruikt in korte kuren bij actief eczeem, met een sterkte afgestemd op de locatie (mild op het gezicht, sterker op dikke of gelichenificeerde huid), zijn deze veilig en effectief. De huidverdunning waar mensen bang voor zijn, komt van langdurig ononderbroken gebruik van sterke steroïden op kwetsbare gebieden, niet van het volgens voorschrift behandelen van opflakkeringen.
The study · 1
Fishbein et al., systematic review of topical corticosteroids in paediatric atopic dermatitis · J Pediatr Nurs 2019;47:36-43
Calcineurinecrèmes verbeterden vijf tot zes van de zeven eczeemuitkomsten zonder de huid dunner te maken
Tacrolimus- en pimecrolimuszalven zijn een steroïdvrije manier om eczeem onder controle te houden, en ze werkten bij de meeste uitkomsten net zo goed als steroïdcrèmes met middelmatige sterkte. Omdat ze de huid niet dunner maken, zijn ze geschikt voor het gezicht, de oogleden en huidplooien.
De netwerkmeta-analyse van AAAAI/ACAAI uit 2023 evalueerde 68 interventies over 219 onderzoeken. Pimecrolimus verbeterde zes van de zeven uitkomsten (bij twee behorend tot de beste), tacrolimus 0.1% verbeterde er vijf (bij twee behorend tot de beste), en beide behoorden, samen met steroïden van middelmatige sterkte, tot de meest effectieve voor het behouden van controle, alle met bewijs van hoge zekerheid en zonder toename van schade. Hun voordeel ten opzichte van steroïden is anatomisch: ze veroorzaken geen huidatrofie, dus ze worden gebruikt waar langdurige steroïden risicovol zijn. Een voorbijgaand branderig of prikkend gevoel bij het aanbrengen is de meest voorkomende vroege klacht.
Dit is de eerste keuze voor eczeem op dunne huid, het gezicht, de oogleden en plooien, waar ze de verdunning vermijden die sterke steroïden kunnen veroorzaken. Een kortdurend prikkend gevoel bij het eerste gebruik verdwijnt meestal binnen een week.
The study · 1
Chu et al., Topical treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials · J Allergy Clin Immunol 2023;152(6):1493-1519
Dupilumab cleared or nearly cleared the skin in 36 to 38% versus 8 to 10% on placebo
For eczema that covers much of the body and does not respond to creams, the injected biologic dupilumab clears or nearly clears the skin in about a third of people, against under one in ten on placebo, and it calms the itch alongside it.
SOLO 1 (671 patients) and SOLO 2 (708 patients) randomized adults with moderate-to-severe atopic dermatitis to weekly or fortnightly dupilumab 300 mg or placebo for 16 weeks. The co-primary clear/almost-clear outcome was reached by 36-38% on dupilumab versus 8-10% on placebo, with significantly more achieving a 75% improvement in the Eczema Area and Severity Index, and improvements in pruritus, anxiety, depression and quality of life. Dupilumab blocks interleukin-4 and interleukin-13 signaling, the type-2 inflammation central to eczema. Injection-site reactions and conjunctivitis were more common than with placebo.
This is a specialist-prescribed option for eczema that is extensive or unresponsive to topical treatment, not a first step; it is given by injection and continued long term while it works.
The study · 1
Simpson et al., Two phase 3 trials of dupilumab versus placebo in atopic dermatitis · N Engl J Med 2016;375(24):2335-2348
Oral JAK inhibitors eased itch faster than dupilumab, 48% versus 26% at two weeks
The newer oral JAK-inhibitor tablets, such as abrocitinib and upadacitinib, work fast and strongly on severe eczema, easing itch within a couple of weeks and, in a direct comparison, clearing skin faster than the injected biologic. They need blood-test monitoring and specialist supervision.
This double-blind phase 3 trial randomized 727 adults to oral abrocitinib 200 mg daily or subcutaneous dupilumab 300 mg fortnightly for 26 weeks, both on background topical therapy. Abrocitinib produced greater early itch response (PP-NRS4 at week 2: 48% versus 26%, difference 22.6%) and greater EASI-90 at week 4 (29% versus 15%). JAK inhibitors block cytokine signaling broadly, which brings speed but also a class safety profile, boxed warnings covering serious infections, blood clots, cardiovascular events and malignancy drawn largely from an older rheumatoid-arthritis population, that requires baseline and periodic blood monitoring.
A specialist option for severe eczema when fast relief matters or biologics have not been enough; it is a daily tablet with required blood monitoring, so it belongs in a dermatology clinic, not a self-directed plan.
The study · 1
Reich et al., abrocitinib versus dupilumab in atopic dermatitis (JADE DARE) · Lancet 2022;400(10348):273-282
Dagelijkse vochtinbrengende crème halveerde ongeveer de eczeemopflakkeringen en verlengde de tijd tot een opflakkering van 30 naar 180 dagen
Using a moisturizer every day, all over, is the foundation of eczema care. In the trials it roughly halved flares, pushed the next flare from about a month away to about six months away, and cut how much steroid cream people needed.
De Cochrane-review voegde de gegevens samen van 77 gerandomiseerde onderzoeken (6603 deelnemers). Vochtinbrengende crème versus geen vochtinbrengende crème verlaagde de SCORAD-ernstscore bescheiden (3 studies, gemiddeld verschil -2.42), een verandering onder de vooraf vastgestelde belangrijke drempel, maar de uitkomsten voor opflakkeringen en steroïdbesparing waren de praktisch betekenisvolle: minder opflakkeringen (RR 0.40), mediane tijd tot opflakkering 180 versus 30 dagen, en 9.3 g minder gebruikt lokaal corticosteroïd. Het toevoegen van een actief ontstekingsremmend middel aan een vochtinbrengende crème werkte beter dan de vochtinbrengende crème alleen. De meeste opgenomen studies werden beoordeeld met een hoog of onduidelijk risico op bias en de zekerheid was laag, waarom dit op matig staat, niet sterk.
De hoeveelheid is belangrijker dan het merk: breng een gewone vochtinbrengende crème royaal en vaak aan, en blijf dit doen wanneer de huid er schoon uitziet, want dat is wat de volgende opflakkering tegenhoudt.
The study · 1
van Zuuren et al., Emollients and moisturisers for eczema (Cochrane review) · Cochrane Database Syst Rev 2017;2:CD012119
Angst voor steroïdcrèmes verhoogde de therapieontrouw naar 49% tegenover 14%, waardoor eczeem onderbehandeld bleef
Angst voor steroïdcrèmes komt zeer vaak voor, en het is een belangrijke oorzaak dat eczeem slecht blijft: mensen die bang zijn voor de crème gebruiken er veel minder van, waardoor hun eczeem niet tot bedaren komt. De crème zelf is hier niet het probleem; het niet gebruiken ervan wel.
De review bracht 16 cross-sectionele studies samen. De gerapporteerde prevalentie van steroïdangst varieerde sterk (21.0% tot 83.7%), deels omdat studies dit verschillend definieerden, van redelijke voorzichtigheid tot irrationele angst. Waar therapietrouw werd gemeten, hadden de groepen met angst ongeveer drie tot vier keer zoveel therapieontrouw. De informatie die de angst aanwakkerde, kwam van artsen, familie, media en internet. Dit is een bewering over overtuigingen en gedrag, geen behandeleffect, dus het draagt geen richting.
The study · 1
Li et al., Topical corticosteroid phobia in atopic dermatitis: a systematic review · JAMA Dermatol 2017;153(10):1036-1042
Onderhoudsbehandeling twee keer per week verschoof de volgende opflakkering van 15 naar 142 dagen verder
Zodra eczeem tot rust is gekomen, houdt het twee keer per week aanbrengen van de ontstekingsremmende crème op de gebruikelijke probleemplekken het rustig. In het onderzoek verschoof dit de volgende opflakkering van ongeveer twee weken naar bijna vijf maanden verder.
After an open-label settling phase, 224 adults in remission were randomized to twice-weekly tacrolimus 0.1% (n=116) or vehicle (n=108) for 12 months, treating flares openly when they occurred. Proactive treatment reduced the number of disease exacerbations needing substantial intervention (median difference 2, p<0.001), lowered the proportion of treatment days, and extended median time to first flare to 142 versus 15 days. Adverse events were similar between arms. The same proactive principle is applied with intermittent topical steroids and is a standard guideline strategy for recurrent eczema.
The move is to keep treating the skin that keeps flaring even after it looks normal: two applications a week to those spots, not waiting for the next flare and starting over.
The study · 1
Wollenberg et al., Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment · Allergy 2008;63(7):742-750
Dilute bleach baths cut clinician-rated eczema severity by about 22%, and water baths did nearly as well
A twice-weekly bath with a small amount of household bleach, about half a cup in a full tub, modestly calms moderate-to-severe eczema, mostly the visible severity a clinician scores. Whether it helps itch or sleep is not clear, and plain water baths did nearly as well.
The Bayesian meta-analysis pooled 10 RCTs (307 participants, median trial duration 6 weeks) of bleach versus no-bleach baths. Bleach baths probably improved the Eczema Area and Severity Index by a relative 22% (ratio of means 0.78, moderate certainty) and may slightly reduce Staphylococcus aureus colonization (RR 0.89, low certainty). Patient-reported severity, itch, sleep, quality of life and flare risk did not clearly differ, at low to very low certainty. Here the comparator was water baths, which were nearly as effective, so much of the benefit may be the bathing-and-moisturizing routine itself, not the bleach.
Worth trying for moderate-to-severe eczema that keeps getting infected, at roughly half a cup of standard bleach in a full bath, two or three times a week, followed by rinsing and moisturizing. Plain lukewarm baths followed by moisturizer capture most of the same benefit if the bleach is off-putting.
The study · 1
Bakaa et al., Bleach baths for atopic dermatitis: a systematic review and meta-analysis including unpublished data, Bayesian interpretation, and GRADE · Ann Allergy Asthma Immunol 2022;128(6):660-668.e9
Food-elimination diets gave at most a slight 9% gain and can trigger new food allergy
Cutting foods out of the diet does little for eczema, and it can backfire. Across the trials the improvement was small and may not be noticeable, and dropping a food such as egg or milk can lead to a food allergy to it later.
The systematic review pooled 10 RCTs (599 participants; median study mean age 1.5 years, median SCORAD 20.7). Compared with no elimination, dietary elimination gave a low-certainty, slight improvement in eczema severity (risk difference 9%, CI 0 to 17), pruritus and sleeplessness, with no credible difference between empiric elimination and testing-guided elimination or by sensitization status. Harms were poorly reported within the trials, but indirect evidence indicates that removing a food from a child who was tolerating it can lead to loss of tolerance and IgE-mediated allergy on reintroduction. Eczema is a skin-barrier and immune condition; food allergy is a common coexisting problem but is rarely the driver of the eczema itself, so broad elimination trades a small possible gain for nutritional and allergy risk. This finding is two-sided, so it carries no single direction.
Skip cutting out foods and treat the skin instead: emollients and anti-inflammatory creams do far more. Keep a food on board unless a clear, immediate reaction or a clinician's assessment points to it, because removing a tolerated food is what creates the allergy people fear.
The study · 1
Oykhman et al., Dietary elimination for the treatment of atopic dermatitis: a systematic review and meta-analysis · J Allergy Clin Immunol Pract 2022;10(10):2657-2666.e8
Daily baby moisturizer did not prevent eczema in at-risk infants, 31% versus 28%
Moisturizing a baby from birth was hoped to head off eczema before it starts. In the large trial that tested it, it did not: eczema was just as common in the babies who were moisturized daily. Moisturizers treat eczema well, but they do not prevent it.
BEEP randomized 1394 high-risk term infants to daily emollient plus standard advice or standard advice alone for the first year, with follow-up to age 5. Clinical eczema between 12 and 60 months occurred in 31% of the emollient group versus 28% of controls (adjusted RR 1.10), and food allergy, asthma and hay fever were similar between groups. This mirrors the wider Cochrane conclusion that skin-care interventions in infancy do not prevent eczema and may modestly increase skin infections. It is a clean example of a plausible prevention idea not surviving a large trial, and it shows that emollients work as treatment, not as prophylaxis.
The study · 1
Bradshaw et al., Emollients for prevention of atopic dermatitis: 5-year findings from the BEEP randomized trial · Allergy 2023;78(4):995-1006
Probiotica maakten weinig of geen verschil aan eczeem dat je al hebt, over 39 trials
Probiotische supplementen lossen eczeem dat je al hebt niet op. Door 39 trials te poolen, maakten ze weinig of geen verschil aan hoe jeukerig of erg het eczeem was, of aan kwaliteit van leven.
De Cochrane-review uit 2018 omvatte 39 RCT's (2.599 deelnemers, eerste levensjaar tot 55 jaar, slechts zes studies bij volwassenen) van probiotica versus geen probiotica, placebo of andere behandeling voor het behandelen van eczeem. Probiotica toonden weinig of geen verschil in door deelnemers of ouders beoordeelde eczeemklachten aan het einde van de behandeling, en geen betekenisvolle verandering in kwaliteit van leven, waarbij het bewijs als laag tot matige zekerheid werd beoordeeld. Trial-sequentiële analyse ondersteunde dat het symptoomresultaat waarschijnlijk niet zou veranderen met meer vergelijkbare trials. Dit is een afzonderlijke vraag van preventie bij hoog-risico zuigelingen, waar het bewijs apart en meer gemengd is.
The study · 1
Makrgeorgou et al., Probiotics for treating eczema (Cochrane review) · Cochrane Database Syst Rev 2018;11:CD006135
Wet wraps can calm a severe flare quickly, on low-quality evidence from six small trials
Wrapping steroid-treated skin in a damp then dry layer can calm a severe flare fast, and it is a recognized hospital and short-course technique. The formal evidence that it beats ordinary steroid treatment is thin, and it can slightly raise the chance of a mild skin infection.
The review located only six RCTs, each small (19 to 51 patients), comparing wet-wrap therapy with conventional topical treatment. Severity and quality-of-life reporting was incomplete and heterogeneous, and overall certainty was low, so a clear advantage over topical steroids alone could not be established. A non-significant trend toward mild skin infection was seen (RR 6.35, wide CI 0.83 to 48.55). In practice wet wraps are used as a short-term intensive measure for severe or refractory flares, often under specialist guidance, not as routine daily care.
This is a short-term rescue technique for a severe flare, not everyday care: applied for a few days over emollient and steroid, ideally with guidance the first time, and stopped once the skin settles.
The study · 1
Gonzalez-Lopez et al., Efficacy and safety of wet wrap therapy for patients with atopic dermatitis: a systematic review and meta-analysis · Br J Dermatol 2017;177(3):688-695
Narrowband UVB light treatment eased eczema and itch, on low-certainty evidence
For eczema that covers a lot of skin and is not settling with creams, a course of narrowband UVB light at a dermatology clinic calmed the eczema and eased the itch in the trials. It sits between the creams and the strong systemic drugs, and it means regular trips to the clinic.
The 2021 Cochrane review pooled 32 RCTs (1219 participants, aged 5 to 83, mean 28, recruited mostly from dermatology clinics, average 13 weeks of treatment). Narrowband UVB was the most-studied of the light treatments (13 trials). Against placebo or no treatment it improved physician-assessed signs (mean difference -9.4 on a 0 to 90 scale; 1 trial, 41 participants), the number of people reporting reduced itch (risk ratio 1.72; 1 trial, 40 participants), and global improvement (risk ratio 2.81, 95% CI 1.10 to 7.17; 1 trial, 41 participants), with no difference in withdrawals for side effects. Each of these key comparisons rested on a single small trial and the certainty was low. Comparisons of narrowband UVB against UVA1 and PUVA were very low certainty. Phototherapy is a guideline-recognized second-line option, delivered as repeated short sessions over weeks, used when topical treatment is not enough and before or instead of systemic drugs.
Who this may not transfer to:Participants were mostly secondary-care dermatology patients with more troublesome eczema, so this reflects second-line clinic use, not mild eczema managed at home; the key narrowband UVB findings each rest on a single small trial.
This is a clinic-based option for widespread eczema that topicals have not controlled, given as repeated short light sessions over several weeks. It avoids systemic medicines but needs regular visits, and the total ultraviolet dose over the years is kept in mind because cumulative UV ages the skin and adds to skin-cancer risk.
The study · 1
Musters et al., Phototherapy for atopic eczema (Cochrane review) · Cochrane Database Syst Rev 2021;10(10):CD013870
Chinese herbal medicine modestly raised recovery rates but did not move standardized severity scores
Chinese herbal formulas showed a modest edge in the pooled trials, more people rated as recovered and fewer relapses, but the harder severity measures did not clearly move, and most trials were small and of limited quality. It is a promising signal, not settled evidence.
The 2023 meta-analysis pooled 17 RCTs (1624 patients). Chinese herbal medicine raised the overall recovery rate (RR 1.15) and reduced recurrence (OR 0.19), both robust to sensitivity analysis, with adverse-event rates no different from controls. But the objective severity scales told a weaker story: no significant difference on EASI or quality of life, and the SCORAD improvement did not survive sensitivity analysis. Most trials were small and conducted in single regions, which is why this sits at emerging. Earlier Cochrane reviews reached a more cautious conclusion of insufficient evidence. A separate, serious concern is that some marketed herbal eczema products have been found adulterated with undeclared corticosteroids, so the safety of an unverified product is not the safety of the studied formula.
Who this may not transfer to:The trials were almost all conducted in China and did not report results by sex; how far the formulas and findings transfer to other populations and to each sex is not established.
If you want to explore herbal treatment, do it through a qualified practitioner using a traceable supply, not an unlabeled cream bought online, because adulteration with hidden steroids is a documented problem in this market.
The study · 1
Jia et al., An updated systematic review and meta-analysis of efficacy and safety of Chinese herbal medicine for treating atopic dermatitis · J Dermatolog Treat 2023;34(1):2268766
Vitamin D supplementation modestly improved eczema severity, most in people who run low
People with eczema tend to run lower on vitamin D, more so when the eczema is bad, and taking vitamin D modestly improved severity in the trials. It is a low-risk add-on worth considering, especially if you are deficient, not a substitute for skin treatment.
The meta-analysis of 20 studies (1882 AD cases) found significantly lower serum 25(OH)D in people with eczema than controls, lower still in severe versus mild-to-moderate disease, and a significant improvement in severity with supplementation. The authors caution that season, sunlight exposure and cultural practices confound the vitamin-D-and-eczema relationship, and that the randomized evidence on supplementation is still limited, which keeps this at emerging. The plausible mechanism is vitamin D's role in the skin barrier and antimicrobial peptide production, but causal direction is not settled.
A daily vitamin D supplement is cheap, safe at standard doses and reasonable to try as an adjunct, particularly through darker months or if a blood test shows you are low; treat the skin as the main task and view this as a possible extra.
The study · 1
Ng and Yew, vitamin D and atopic dermatitis: systematic review and meta-analysis · Am J Clin Dermatol 2022;23(3):267-275
How it works
Eczema begins in a faulty skin barrier and a type-2 immune overreaction, not the diet
Eczema starts in the skin barrier, not the diet. A common genetic fault in a skin protein called filaggrin lets moisture out and irritants in, and the immune system then overreacts, which is why relentless moisturizing and calming the inflammation are the two things that work.
Atopic dermatitis affects around 20% of children and 5% of adults. The outermost skin layer, the stratum corneum, normally keeps water in and allergens and microbes out. Loss-of-function FLG mutations are the key inherited risk factor, weakening that barrier; type-2 inflammatory cytokines (including interleukin-4 and interleukin-13) then suppress other barrier genes, change the lipid composition, and drive the itch-scratch cycle. The barrier defect lets in allergens and lets Staphylococcus overgrow, feeding the inflammation. This mechanism is why the treatments that work target the barrier (emollients) and the type-2 inflammation (steroids, calcineurin inhibitors, dupilumab), and why treating the skin, not hunting a food, is the foundation.
The study · 1
Stefanovic and Irvine, the role of the skin barrier in atopic dermatitis · Ann Allergy Asthma Immunol 2024;132(2):187-195
What Does Not Help
A few widely tried approaches do little for eczema, and one carries a risk of its own. Broad food-elimination diets are the big one. Cutting foods out barely helps, and it can backfire. Across the trials the improvement was slight and may not be noticeable, at most about a 9% gain. Guiding the elimination by allergy tests gave no advantage. The main harm falls on children. Cutting out a food a child was eating safely, such as egg or milk, can trigger a sudden allergic reaction when it is reintroduced. A broad elimination diet risks that allergy and poor nutrition for very little benefit. A clear, immediate reaction to a food is a separate matter that does warrant assessment.
Daily moisturizer from birth was hoped to head off eczema before it starts. In the large trials that tested it in babies at high family risk, it did not. Eczema was just as common in the infants moisturized daily as in those who were not, 31% against 28%. The later atopic conditions were no less common either. Moisturizers treat eczema that has already appeared; they do not prevent it.
Probiotic supplements do not clear eczema you already have. Pooling 39 trials, they made little or no difference to how itchy or bad the eczema was, or to quality of life. Taking probiotics in pregnancy or infancy to try to prevent eczema is a separate and more contested question.
How It Works
Eczema runs on two faults that make each other worse: a leaky skin barrier and a type-2 immune overreaction. The outermost skin layer, the stratum corneum, normally keeps water in and allergens and microbes out. Loss-of-function mutations in the filaggrin gene are the main inherited risk, weakening that barrier. Many people with eczema have normal filaggrin, so the gene raises risk without accounting for every case. Once the barrier leaks, type-2 inflammatory signals, chiefly interleukin-4 and interleukin-13, suppress other barrier genes, change the skin's lipids, and drive the itch. The damaged barrier also lets Staphylococcus bacteria overgrow, adding to the inflammation.
This is why the treatments that work target one or both faults. Emollients rebuild the barrier from the outside. Steroids and calcineurin inhibitors calm the local inflammation. Dupilumab blocks interleukin-4 and interleukin-13 directly, and the JAK inhibitors block the signaling those cytokines use. Hunting through the diet for a food to cut out does nothing for the barrier or the immune response, the actual problem.
Go Deeper
- Vitamin D: the low-risk supplement that modestly improved eczema severity, and where it fits as an adjunct.
- Whole foods: eating for skin and general health without the risks of cutting whole foods out on the strength of an eczema hunch.
- The oral and skin microbiome: how the microbes living on us shape inflammation, the backdrop to why probiotics have been tried and why Staphylococcus matters in eczema.
- Asthma: the airway end of the atopic march that so often travels with eczema.
- Hay fever and allergic rhinitis: the other common companion of eczema, and how it is managed on its own terms.
The Chinese Medicine View
Chinese medicine never read eczema as one thing. It is an established classical dermatology domain, named 濕疹 shī zhěn. This is Chinese medicine's own way of reading the same flaring, settling skin, by the person's constitution and how the skin is behaving. Diagnosis by pattern needs an in-person examination, so a qualified practitioner working from a traceable herbal supply is the way to use it.
The acute flare is red, weeping and intensely itchy, the kind a dermatologist treats. Chinese medicine reads it as damp-heat: heat in the skin and damp in the ooze, worse in heat and humidity. The direction of treatment is to clear the heat and drain the damp.
The chronic end is different. Dry, thickened, leathery skin that itches worse at night is the lichenified eczema of years of scratching. Chinese medicine reads it as blood deficiency with dryness and wind: too little blood to moisten the skin, with wind driving the itch. The direction is to nourish blood, moisten dryness and settle the wind. Two other patterns sit between these: wind-heat for a sudden widespread eruption, and spleen deficiency with damp for the pale, puffy, oozing skin often seen in children.
The Western and Chinese readings sit side by side; neither proves the other. The trial evidence for Chinese herbal formulas in eczema is emerging and quality-limited. The pooled studies showed more people rated as recovered and fewer relapses. But the stricter, measured severity scores barely changed, and most trials were small and single-region. It is a promising signal that better trials have yet to confirm.
The main safety concern here is the product itself. Some marketed herbal eczema creams, particularly unlabeled or imported ones, have been found adulterated with undisclosed potent steroids. An unverified product carries none of the assurances of the studied formula. Explore herbal treatment through a qualified practitioner working from a regulated, traceable supply.
Cautions
Extra restraintEverything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
Het gevreesde verband met kanker bij calcineurinecrèmes bleek niet aanwezig bij 3.4 miljoen patiënten
Als onderdeel van de Amerikaanse allergie-immunologierichtlijnen voor atopische dermatitis van 2022 voegden reviewers de gegevens samen van 110 studies (52 RCT's, 69 niet-gerandomiseerd), met in totaal ongeveer 3.4 miljoen patiënten die gemiddeld 11 maanden werden gevolgd. Met behulp van Bayesiaanse modellen tegen door patiënten vastgestelde drempels werd het absolute kankerrisico niet verhoogd door blootstelling aan lokale calcineurineremmers. De oorspronkelijke regelgevende waarschuwing uit 2006 was uit voorzorg, geëxtrapoleerd vanuit orale immunosuppressie bij transplantatiepatiënten en dierstudies met veel hogere systemische blootstelling dan een huidcrème veroorzaakt.Devasenapathy et al., Cancer risk with topical calcineurin inhibitors for atopic dermatitis: a systematic review and meta-analysis
Eczema herpeticum: snel verspreide, pijnlijke, uitgestanste laesies die dezelfde-dag antivirale zorg nodig hebben
Een subset van mensen met atopische dermatitis ontwikkelt eczema herpeticum, een wijdverspreide herpes-simplex-virusinfectie over eczeemhuid die kan leiden tot ernstige, soms fatale complicaties. Het wordt bevorderd door de type-2-immuunverschuiving, verzwakte antimicrobiële peptiden (verminderde humane bèta-defensinen en LL-37), filaggrinebarrièredefecten en Staphylococcus aureus-overvloed die ernstigere eczeem kenmerken. Klinisch verslechtert het snel, is het pijnlijk, met monomorfische koepelvormige blaasjes en uitgestanste erosies, frequent met koorts en malaise, en het rechtvaardigt spoedeisende systemische antivirale therapie (aciclovir). Dupilumab-behandeling vermindert het risico. Dit is een veiligheidsbewering, geen behandeleffect, dus het heeft geen richting.Traidl et al., Eczema herpeticum in atopic dermatitis
Getting the steroid strength right
Topical steroids are matched to the site: mild on the face, eyelids and skin folds, stronger on thick or lichenified skin. Prolonged potent steroids on delicate areas can thin the skin. On the face or genitals, prolonged potent use can cause topical steroid withdrawal, an uncommon reaction a regulator flagged in 2021. That is a reason to step down with guidance. Correct short courses on active eczema do not cause it. If you find yourself using a strong steroid continuously, that is the point to review the plan with a clinician.
Unlabeled creams and hidden steroids
Some "natural" or imported eczema creams sold online have been found to contain undisclosed potent steroids. An unlabeled product can be far stronger than it appears, applied in the wrong place and for too long without anyone knowing. If an unlabeled cream works suspiciously well, have it and your skin reviewed.
The severe-disease drugs are specialist-monitored
Dupilumab and the oral JAK inhibitors are for moderate-to-severe eczema and are prescribed and monitored by a specialist. Dupilumab can cause conjunctivitis and injection-site reactions. The JAK inhibitors carry class boxed warnings covering serious infections, blood clots, cardiovascular events and malignancy, drawn largely from an older rheumatoid-arthritis population, and need baseline and periodic blood monitoring. The choice weighs speed against that safety profile with a dermatologist.
Eczema is miserable and often affects children, and none of this is meant to frighten you off treatment. Most people control it well with steady moisturizing and the right cream, used properly and without fear.
When to See Someone
Most eczema is managed with the moisturizers, creams and habits above and never needs more. These are the situations where a professional is the right next step, and the first three need care the same day.
- Rapidly spreading, painful skin with clusters of uniform, punched-out sores or blisters, usually with fever and feeling unwell. This can be eczema herpeticum, a herpes infection of eczema-affected skin, and it is a medical emergency needing urgent antiviral treatment(seek urgent care)
- Widespread weeping, yellow crusting, spreading redness, pain or fever: signs of an infected flare that needs treatment, and steroid alone will not clear it(seek urgent care)
- Eczema turning red and inflamed over almost the whole body, with shivering or feeling unwell (erythroderma): get urgent assessment(seek urgent care)
- In a baby or young child, poor weight gain or faltering growth alongside severe or widespread eczema, which needs a proper assessment
- A severe flare that will not settle with your usual treatment, or eczema that is not improving at all despite using the creams correctly
- Eczema on or around the eyes with any change in vision, or eyelid skin that is not settling
- If you have been using an unlabeled or imported "natural" eczema cream, some of which have been found to contain undisclosed potent steroids, have the cream and your skin reviewed by a professional
- Adult-onset eczema that is spreading or behaving oddly, or a single patch that will not clear, a clinician should confirm it is eczema
Eczema is common and manageable, and most flares never reach this point. Knowing the few signs that need same-day care is simply part of managing it with confidence.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 18 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.